Thrombophilic state in cancer, Part I: Biology, incidence, and risk factors

Journal of Surgical Oncology

Volumn 104, Issue 3, 2011, Pages 316-322

  Dipasco, Peter J ^a   Misra, Subhasis ^a   Koniaris, Leonidas G ^a   Moffat Jr , Frederick L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

cancer biology; risk factors; thromboembolism; thrombophilic state

Indexed keywords

BEVACIZUMAB; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; CANCER PROCOAGULANT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; FLUOROURACIL; METHOTREXATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXALIPLATIN; PACLITAXEL; PLASMIN; PROCOAGULANT; RECOMBINANT ERYTHROPOIETIN; TAMOXIFEN; THROMBOPLASTIN; VASCULOTROPIN;

ANTIANGIOGENIC THERAPY; BLEEDING; BLOOD CLOTTING; BLOOD VESSEL INJURY; BLOOD VISCOSITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER SURGERY; CELL ADHESION; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; ERYTHROCYTE TRANSFUSION; EXTRACELLULAR MATRIX; FIBRIN FORMATION; FIBRINOLYSIS; GENE INACTIVATION; HORMONAL THERAPY; HUMAN; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; NEOPLASM; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOPHLEBITIS; THROMBOSIS; TUMOR CELL; TUMOR GROWTH; VASCULAR ACCESS DEVICE; VENOUS THROMBOEMBOLISM;

HUMANS; INCIDENCE; NEOPLASMS; RISK FACTORS; THROMBOPHILIA;

EID: 80051544791     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21925     Document Type: Review

References (69)

1. Weitz IC, Liebman HA,: The role of oral anticoagulants in tumor biology. Semin Thromb Hemost 2007; 33: 695-698. (Pubitemid 350157014)
2. Zielinski CC, Hejna M,: Warfarin for cancer prevention. N Engl J Med 2000; 342: 1991-1993. (Pubitemid 30419098)
3. Morrison M,: An analysis of the blood picture in 100 cases of malignancy. J Lab Clin Med 1932; 17: 1071-1093.
4. Korte W,: Cancer and thrombosis: an increasingly important association. Support Care Cancer 2008; 16: 223-228.
5. Heit JA,: Cancer and venous thromboembolism: Scope of the problem. Cancer Control 2005; 12: 5-10. (Pubitemid 41356174)
6. Baron JA, Gridley G, Weiderpass E, et al.: Venous thromboembolism and cancer. Lancet 1998; 351: 1077-1080. (Pubitemid 28163410)
7. Carroll VA, Binder BR,: The role of the plasminogen activation system in cancer. Semin Thromb Hemost 1999; 25: 183-197. (Pubitemid 29227147)
8. Heit JA, Silverstein MD, Mohr DN, et al.: Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. Arch Intern Med 2000; 160: 809-815. (Pubitemid 30165241)
9. Schmitt M, Kuhn W, Harbeck N, et al.: Thrombophilic state in breast cancer. Semin Thromb Hemost 1999; 25: 157-166. (Pubitemid 29227144)
10. Falanga A, Rickles FR,: Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999; 25: 173-182. (Pubitemid 29227146)
11. Boccaccio C, Comoglio PM,: Genetic link between cancer and thrombosis. J Clin Oncol 2009; 27: 4827-4833.
12. Edwards RL, Rickles FR, Moritz TE, et al.: Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol 1987; 88: 596-602. (Pubitemid 18014618)
13. Kasthuri RS, Taubman MB, Mackman N,: Role of tissue factor in cancer. J Clin Oncol 2009; 27: 4834-4838.
14. Bick RL,: Cancer-associated thrombosis. N Engl J Med 2003; 349: 109-111. (Pubitemid 36818779)
15. Kuderer NM, Ortel TL, Francis CW,: Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol 2009; 27: 4902-4911.
16. Amirkhosravi A, Meyer T, Amaya M, et al.: The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin Thromb Hemost 2007; 33: 643-652. (Pubitemid 350157007)
17. Honn KV, Tang DG, Crissman JD,: Platelets and cancer metastasis: A causal relationship? Cancer Metastasis Rev 1992; 11: 325-351.
18. Gordon SG, Chelladurai M,: Non-tissue factor procoagulants in cancer cells. Cancer Metastasis Rev 1992; 11: 267-282.
19. Falanga A, Marchetti M,: Heparin in tumor progression and metastatic dissemination. Semin Thromb Hemost 2007; 33: 688-694. (Pubitemid 350157013)
20. Kwaan HC, Bongu A,: The hyperviscosity syndromes. Semin Thromb Hemost 1999; 25: 199-208. (Pubitemid 29227148)
21. Levine M,: Treatment of thrombotic disorders in cancer patients. Haemostasis 1997; 27: 38-43. (Pubitemid 27521235)
22. Khorana AA, Francis CW, Culakova E, et al.: Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007; 110: 2339-2346. (Pubitemid 350100757)
23. Khorana AA, Connolly GC,: Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 2009; 27: 4839-4847.
24. Levitan N, Dowlati A, Remick SC, et al.: Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78: 285-291. (Pubitemid 29439263)
25. Rickles FR, Edwards RL,: Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983; 62: 14-31. (Pubitemid 13070586)
26. Blom JW, Doggen CJ, Osanto S, et al.: Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-722. (Pubitemid 40216041)
27. Alcalay A, Wun T, Khatri V, et al.: Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol 2006; 24: 1112-1118. (Pubitemid 46638808)
28. Agnelli G, Bolis G, Capussotti L, et al.: A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: The @RISTOS project. Ann Surg 2006; 243: 89-95. (Pubitemid 43054059)
29. Rodriguez AO, Wun T, Chew H, et al.: Venous thromboembolism in ovarian cancer. Gynecol Oncol 2007; 105: 784-790. (Pubitemid 46734211)
30. Blom JW, Vanderschoot JP, Oostindier MJ, et al.: Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: Results of a record linkage study. J Thromb Haemost 2006; 4: 529-535.
31. Chew HK, Wun T, Harvey D, et al.: Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166: 458-464.
32. Kroger K, Weiland D, Ose C, et al.: Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 2006; 17: 297-303. (Pubitemid 43160121)
33. Khorana AA, Francis CW, Culakova E, et al.: Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006; 24: 484-490. (Pubitemid 46630468)
34. Cohen AT, Tapson VF, Bergmann JF, et al.: Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): A multinational cross-sectional study. Lancet 2008; 371: 387-394. (Pubitemid 351173321)
35. Monreal M, Kakkar AK, Caprini JA, et al.: The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients. Findings from the RIETE registry. J Thromb Haemost 2004; 2: 1892-1898. (Pubitemid 40192740)
36. Starling N, Rao S, Cunningham D, et al.: Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: A report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 2009; 27: 3786-3793.
37. Zangari M, Siegel E, Barlogie B, et al.: Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: Implications for therapy. Blood 2002; 100: 1168-1171. (Pubitemid 34864267)
38. Rogers SO Jr, Kilaru RK, Hosokawa P, et al.: Multivariable predictors of postoperative venous thromboembolic events after general and vascular surgery: Results from the patient safety in surgery study. J Am Coll Surg 2007; 204: 1211-1221. (Pubitemid 46819093)
39. Pritchard KI, Paterson AH, Paul NA, et al.: Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 1996; 14: 2731-2737. (Pubitemid 26329659)
40. Mandala M, Falanga A, Roila F,: Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann Oncol 2009; 20: 182-184.
41. Mandara MT, Pavone S, Mandrioli L, et al.: Matrix metalloproteinase-2 and matrix metalloproteinase-9 expression in canine and feline meningioma. Vet Pathol 2009; 46: 836-845.
42. Baum M, Budzar AU, Cuzick J, et al.: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002; 359: 2131-2139. (Pubitemid 34694019)
43. Braithwaite RS, Chlebowski RT, Lau J, et al.: Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003; 18: 937-947. (Pubitemid 37510624)
44. Coates AS, Keshaviah A, Thurlimann B, et al.: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 2007; 25: 486-492. (Pubitemid 350002953)
45. Coombes RC, Hall E, Gibson LJ, et al.: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092. (Pubitemid 38298988)
46. ATAC Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45-53.
47. Gradishar WJ,: Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women. Oncology 2005; 69: 1-9. (Pubitemid 41207052)
48. Seaman HE, Langley SE, Farmer RD, et al.: Venous thromboembolism and cyproterone acetate in men with prostate cancer: A study using the General Practice Research Database. BJU Int 2007; 99: 1398-1403. (Pubitemid 47164820)
49. Nalluri SR, Chu D, Keresztes R, et al.: Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis. JAMA 2008; 300: 2277-2285.
50. Scappaticci FA, Skillings JR, Holden SN, et al.: Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99: 1232-1239. (Pubitemid 47299901)
51. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.
52. Shah MA, Ilson D, Kelsen DP,: Thromboembolic events in gastric cancer: High incidence in patients receiving irinotecan-and bevacizumab-based therapy. J Clin Oncol 2005; 23: 2574-2576. (Pubitemid 47053842)
53. Johnson DH, Fehrenbacher L, Novotny WF, et al.: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191. (Pubitemid 41095154)
54. Zangari M, Fink LM, Elice F, et al.: Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 2009; 27: 4865-4873.
55. Hambleton JSJ, Kabbinavar F, Bergsland E, et al.: Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2005; 23: 259s.
56. Hershman DL, Buono DL, Malin J, et al.: Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. J Natl Cancer Inst 2009; 101: 1633-1641.
57. Bohlius J, Wilson J, Seidenfeld J, et al.: Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006; 98: 708-714. (Pubitemid 43821788)
58. Lee AY, Levine MN, Butler G, et al.: Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 2006; 24: 1404-1408. (Pubitemid 46622005)
59. Sorensen HT, Mellemkjaer L, Olsen JH, et al.: Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-1850. (Pubitemid 32104130)
60. Bennett CL, Silver SM, Djulbegovic B, et al.: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299: 914-924. (Pubitemid 351397066)
61. Khorana AA, Francis CW, Blumberg N, et al.: Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008; 168: 2377-2381.
62. Verso M, Agnelli G,: Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21: 3665-3675. (Pubitemid 46594061)
63. Kuter DJ,: Thrombotic complications of central venous catheters in cancer patients. Oncologist 2004; 9: 207-216. (Pubitemid 38452120)
64. Akl EA, Kamath G, Yosuico V, et al.: Thromboprophylaxis for patients with cancer and central venous catheters: A systematic review and a meta-analysis. Cancer 2008; 112: 2483-2492.
65. Verso M, Agnelli G, Kamphuisen PW, et al.: Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients. Intern Emerg Med 2008; 3: 117-122.
66. Eastridge BJ, Lefor AT,: Complications of indwelling venous access devices in cancer patients. J Clin Oncol 1995; 13: 233-238.
67. Gallieni M, Pittiruti M, Biffi R,: Vascular access in oncology patients. CA Cancer J Clin 2008; 58: 323-346.
68. De Cicco M, Matovic M, Balestreri L, et al.: Central venous thrombosis: An early and frequent complication in cancer patients bearing long-term silastic catheter. A prospective study. Thromb Res 1997; 86: 101-113. (Pubitemid 27235123)
69. Tesselaar ME, Ouwerkerk J, Nooy MA, et al.: Risk factors for catheter-related thrombosis in cancer patients. Eur J Cancer 2004; 40: 2253-2259. (Pubitemid 39348875)